Moderna Stock Drops After Cancer Vaccine Data Leaks
Moderna shares fell today after trial numbers leaked early for its new cancer vaccine with Merck.
Moderna stock took a hit today. Investors sold off shares following an early leak of new cancer trial numbers. The drug maker teamed up with Merck to create a custom cancer shot.
The trial results show good news for patients. People who took the shot lived longer without cancer returning. Still, Wall Street wanted even higher numbers from the study. The early data drop caught traders off guard, which sparked a fast selloff.
Moderna shared the full study soon after the leak. Both companies plan to push ahead with larger trials. They want to bring this treatment to clinic shelves as soon as possible.
Price swings happen when big news breaks ahead of schedule. Smart investors watch the science instead of the daily ticker. New medical treatments take years to prove their full worth.
Source: CNBC
More from Biotech
